Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The 17th February saw the publication of Dr David Keene and Prof Keith Willett's paper "How effective are platelet rich plasma injections in treating musculoskeletal soft tissue injuries?" in the British Medical Journal. The article can be downloaded using the toll free link here

The paper is connected with the PATH-2 study, led by researchers in NDORMS, and forms part of a BMJ series of occasional articles that highlight areas of practice where management lacks convincing supporting evidence.

The key messages of the article include:

  • Routine use of autologous platelet-rich plasma (PRP) is not recommended as there is insufficient evidence of clinical efficacy; instead, its use should be restricted to research settings
  • Ensure patients receiving PRP are aware of the limited evidence of efficacy, so that they can make an informed decision about their care
  • Clinicians should be aware of the concentration of PRP, and yield of bioactive proteins, produced by their selected preparation device

The PATH-2 study is a randomised controlled trial to compare the effects on muscle-tendon function of a standardised PRP preparation versus dry needle injection (control) for non-operatively managed acute Achilles tendon rupture. You can read more about the trial here.

Similar stories

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.